Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Samsung Biologics has attained ISO 22301 certification — the international standard for business continuity management — for additional business operations.

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Managing to ISO 22301 levels is itself a rigorous endeavor and achieving certification is an indication of an organization's robust and sustained ability to prevent, prepare for, respond to, and recover from unexpected and disruptive incidents.

In 2018, Samsung Biologics was the first to achieve ISO 22301 certification in the biologics CMO industries for Plant 1, Plant 2, and support functions as validated by the British Standard Institution (BSI) certification body. Samsung subsequently achieved ISO certification for drug product in 2019, and the latest certification confirms Samsung's business continuity management system (BCMS) and operational resiliency for Plant 3, biotesting and quality control services, and an extended line of small-scale operations in 2020 according to ISO standards.

Expanding its ISO 22301 certification is expected to build greater trust with Samsung for clients who are seeking a reliable manufacturing partner to ensure a stable supply of life-saving drugs. In light of the current pandemic and the race to develop and mass-produce COVID-19 therapies, business continuity and disaster preparedness are growing in importance.

As a part of the BCMS responding to the pandemic, Samsung Biologics established war rooms to proactively manage its global supply chain and employee safety to prevent any potential disruptions to cGMP manufacturing and other business operations.

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more 
AbbVie completes Allergan acquisition

AbbVie completes Allergan acquisition

11 May 2020

Creates biopharmaceutical company with leadership positions in immunology, hematologic oncology, neuroscience, and Allergan aesthetics.

Read more